Physician profile
Thomas Morris
NPI 1972573665
$563.46
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $94.51 · 2021: $186 · 2022: $81.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $107.30 | 2019-2021 | |
| Vertos Medical, INC. | $91.04 | 2019 | |
| Pfizer INC. | $56.70 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.52 | 2022 | |
| Lilly USA, LLC | $43.93 | 2019-2022 | |
| Amgen INC. | $38.50 | 2020-2021 | |
| Glaxosmithkline, LLC. | $33.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $22.81 | 2019-2021 | |
| Organogenesis INC. | $21.31 | 2021 | |
| Abbvie INC. | $19.67 | 2021 | |
| Smith+Nephew, INC. | $18.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.92 | 2019 | |
| Sanofi Pasteur INC. | $16.35 | 2020 | |
| Irhythm Technologies, INC. | $14.33 | 2019 | |
| Eisai INC. | $13.80 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.